Sinco Pharmaceuticals Holdings Limited (06833.HK)

Sinco Pharmaceuticals Holdings Limited is the third largest provider of marketing, promotion and channel management, or MPCM, services in the PRC pharmaceutical industry with a market share of 6.4% based on revenue in 2014, according to the Frost & Sullivan Report. China’s MPCM services market, which had a market size of RMB14,959.8 million in 2014, is a subset of China’s pharmaceutical circulation market and accounted for approximately 1.0% of China’s pharmaceutical circulation market in 2014, according to the Frost & Sullivan Report. We are also China’s only MPCM services provider for plasma-based pharmaceuticals. China’s plasma-based pharmaceutical product market grew at a CAGR of 23.2% from 2010 to 2014, which is faster than the CAGR of both the overall China pharmaceutical market and China’s imported pharmaceutical market during the same period, according to the Frost & Sullivan Report. Driven by the unmet demand for plasma-based pharmaceuticals, favourable government initiatives, market development as well as technological improvements in the manufacturing process in China, the plasma-based pharmaceutical product market is expected to grow at a CAGR of 22.4% from 2015 to 2019 according to the Frost & Sullivan Report.